

## Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[*b*]thiophene (APBT) based stimulants

Simon D. Brandt,<sup>1,\*</sup> Laura Carlino,<sup>1,2</sup> Pierce V. Kavanagh,<sup>3</sup> Folker Westphal,<sup>4</sup> Wolfgang Dreiseitel,<sup>5</sup> Geraldine Dowling,<sup>3,6</sup> Michael H. Baumann,<sup>7</sup> Harald H. Sitte,<sup>8</sup> Adam L. Halberstadt<sup>9,10</sup>

<sup>1</sup> School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK

<sup>2</sup> School of Chemical Engineers, University of Upper Alsace, 68093 Mulhouse, France

<sup>3</sup> Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin 8, Ireland

<sup>4</sup> State Bureau of Criminal Investigation Schleswig-Holstein, Section Narcotics/Toxicology, Mühlenweg 166, D-24116 Kiel, Germany

<sup>5</sup> Hessian State Bureau of Criminal Investigation, Hölderlinstraße 1–5, Wiesbaden, Germany

<sup>6</sup> Department of Life Sciences, School of Science, Sligo Institute of Technology, Ash Lane, Sligo, F91YW50, Ireland


<sup>7</sup> Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA

<sup>8</sup> Medical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Währinger Straße 13a, A-1090 Vienna, Austria.


<sup>9</sup> Department of Psychiatry, University of California San Diego, La Jolla, CA 92093-0804, USA

<sup>10</sup> Research Service, VA San Diego Healthcare System, La Jolla, CA, USA

\* Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E-Mail: s.brandt@ljmu.ac.uk



| <b>Content</b>   | <b>Page</b> |
|--|-------------|
| NMR data of nitrostyrene intermediates (2-, 3-, 5-, and 6-APBT)  | S3          |
| EI mass spectra of all six APBT isomers  | S4          |
| Alternative suggestions for formations of m/z 147 and m/z 97 (EI-MS)   | S5          |
| EI-QqQ-MS/MS spectra of all six APBT isomers using m/z 147 as precursor ion  | S6          |
| Proposed fragmentation pathways (EI-MS/MS of m/z 147)  | S7          |
| Proposed fragmentation pathways (CI-MS)  | S8          |
| CI-QqQ-MS/MS spectra of all six APBT isomers using m/z 149 as precursor ion  | S9          |
| Proposed fragmentation pathways (CI-MS/MS of m/z 149)  | S10         |
| CI-QqQ-MS/MS spectra of all six APBT isomers using m/z 175 as precursor ion  | S11         |
| Proposed fragmentation pathways (CI-MS/MS of m/z 175)  | S12         |
| CI-QqQ-MS/MS spectra of all six APBT isomers using m/z 177 as precursor ion  | S13         |
| Proposed fragmentation pathways (CI-MS/MS formation of m/z 149 from m/z 177)   | S13         |
| Proposed fragmentation pathways (CI-MS/MS of m/z 177)  | S14         |
| Proposed fragments and fragmentation pathways of acetamido and HFB derivatives (GC-MS)   | S15         |
| Proposed fragments and fragmentation pathways of ethoxycarbonyl and methanesulfonamide derivatives (GC-MS)   | S16         |
| ESI single quadrupole mass spectra (in-source CID) of all six APBT isomers and experimental conditions   | S17         |
| QTOF tandem mass spectra of all six APBT isomers   | S18         |
| Calculated masses and molecular formulae obtained from QTOF-MS/MS and proposed fragmentation schemes for some ions derived from 4-, 5-, and 7-APBT | S19         |
| HPLC-DAD UV spectra of all six APBT isomers  | S20         |
| NMR spectra of 2-APBT HCl ( $^1\text{H}$ , $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}$ DEPTQ, HSQC and HMBC)                                     | S21–S25     |
| NMR spectra of 3-APBT HCl ( $^1\text{H}$ , $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}$ DEPTQ, HSQC and HMBC)                                     | S26–S30     |
| NMR spectra of 4-APBT HCl ( $^1\text{H}$ , $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}$ , HSQC and HMBC)  | S31–S35     |
| NMR spectra of 5-APBT HCl ( $^1\text{H}$ , $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}$ DEPTQ, HSQC and HMBC)                                     | S36–S40     |
| NMR spectra of 6-APBT HCl ( $^1\text{H}$ , $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}$ DEPTQ, HSQC and HMBC)                                     | S41–S45     |
| NMR spectra of 7-APBT HCl ( $^1\text{H}$ , $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}$ , HSQC and HMBC)  | S46–S50     |
| IR spectra of 2-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)   | S51–S53     |
| IR spectra of 3-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)   | S54–S56     |
| IR spectra of 4-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)   | S57–S59     |
| IR spectra of 5-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)   | S60–S62     |
| IR spectra of 6-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)   | S63–S65     |
| IR spectra of 7-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)   | S66–S68     |
| IR table: including aromatic ring C-C stretches; aromatic ring C-H in-plane bends; aromatic C-H out-of-plane bends                                 | S69         |
| GC-sIR partial spectra: overtone bands ( $\sim 1700\text{--}2000\text{ cm}^{-1}$ )   | S70         |
| GC-sIR partial spectra: 2- and 3-APBT  | S71         |
| GC-sIR partial spectra: 4- and 7-APBT  | S72         |
| GC-sIR partial spectra: 5- and 6-APBT  | S73         |









| Isomer   | 2                           |                  | 3                                 |                  | 5                                 |                  | 6                                 |                 |
|----------|-----------------------------|------------------|-----------------------------------|------------------|-----------------------------------|------------------|-----------------------------------|-----------------|
| Position | <sup>1</sup> H              | <sup>13</sup> C  | <sup>1</sup> H                    | <sup>13</sup> C  | <sup>1</sup> H                    | <sup>13</sup> C  | <sup>1</sup> H                    | <sup>13</sup> C |
| 2        | -                           | 134.90           | 7.70 (s)                          | 129.03           | 7.56 (d, <i>J</i> = 5.4 Hz)       | 128.06           | 7.59 (d, <i>J</i> = 5.4 Hz)       | 129.28          |
| 3        | 7.68 (s)                    | 132.07           | -                                 | 128.23           | 7.42 (d, <i>J</i> = 5.4 Hz)       | 124.00           | 7.38 (d, <i>J</i> = 5.4 Hz)       | 123.82          |
| 3a       | -                           | 138.62 or 141.94 | -                                 | 138.30           | -                                 | 139.92           | -                                 | 140.23          |
| 4        | 7.91–7.86 (m)               | 124.75           | 7.91 (dist. d, <i>J</i> = 7.8 Hz) | 121.77           | 7.91 (s)                          | 125.46 or 125.48 | 7.88 (d, <i>J</i> = 8.3 Hz)       | 123.98          |
| 5        | 7.49–7.43 (m)               | 126.66 or 125.28 | 7.54–7.51 (m)                     | 125.14 or 125.15 | -                                 | 128.56           | 7.44 (dd, <i>J</i> = 8.3, 1.4 Hz) | 125.95          |
| 6        | 7.49–7.43 (m)               | 126.66 or 125.28 | 7.50–7.47 (m)                     | 125.52           | 7.42 (dd, <i>J</i> = 8.4, 1.6 Hz) | 125.46 or 125.48 | -                                 | 128.43          |
| 7        | 7.91–7.86 (m)               | 122.35           | 7.94 (dist. d, <i>J</i> = 7.8 Hz) | 122.92           | 7.97 (d, <i>J</i> = 8.4 Hz)       | 123.01           | 7.97 (s)                          | 124.43          |
| 7a       | -                           | 138.62 or 141.94 | -                                 | 139.51           | -                                 | 141.29           | -                                 | 140.63          |
| 8        | 8.37–8.36 (m)               | 127.73           | 8.38–8.37 (m)                     | 125.14 or 125.15 | 8.25 (s)                          | 133.98           | 8.22 (s)                          | 133.83          |
| 9        | -                           | 146.17           | -                                 | 148.28           | -                                 | 147.37           | -                                 | 147.37          |
| 10       | 2.66 (d, <i>J</i> = 0.4 Hz) | 14.28            | 2.57 (d, <i>J</i> = 0.8 Hz)       | 14.70            | 2.54 (d, <i>J</i> = 1.0 Hz)       | 14.19            | 2.53 (d, <i>J</i> = 0.9 Hz)       | 14.26           |

Table 1. NMR data for nitrostyrene intermediates (CDCl<sub>3</sub>, 600/150 MHz).




# Supporting Information – Drug Testing and Analysis

## Electron ionization mass spectra of APBT isomers











## Alternative suggestions for m/z 147 and m/z 97 (EI-MS)





# Supporting Information – Drug Testing and Analysis



# Supporting Information – Drug Testing and Analysis







## EI-MS/MS of m/z 147

4-, 5-, 6-, 7-APBT






## Supporting Information – Drug Testing and Analysis




\* m/z 93: possibly from an ethyl phthalate?






## Supporting Information – Drug Testing and Analysis







### CI-MSMS of m/z 149






### 5-APBT



# Supporting Information – Drug Testing and Analysis









## CI-MSMS of m/z 175









## Supporting Information – Drug Testing and Analysis




### CI-MSMS m/z 149 from m/z 177






## Supporting Information – Drug Testing and Analysis

### AC derivatives





### HFB derivatives




## Supporting Information – Drug Testing and Analysis

### EC derivatives




ion 121/ion 115 ratio

|   |      |
|---|------|
| 2 | 0.35 |
| 3 | 0.31 |
| 4 | 1.49 |
| 5 | 2.03 |
| 6 | 1.91 |
| 7 | 1.60 |




### MSA derivatives









## Supporting Information – Drug Testing and Analysis

### In-source CID mass spectra - liquid chromatography electrospray ionization mass spectrometry

This consisted of an Agilent 1100 LC system coupled to a Hewlett Packard/Agilent 1100 MSD (Santa Clara, CA, USA). The following conditions were used: capillary voltage 3500 V, drying gas (N<sub>2</sub>) 12 L/min at 350 °C and nebulizer (N<sub>2</sub>) pressure 50 psig. The mass spectrometer was tuned according to the manufacturer's instructions using ESI Tuning Mix G2421A (Agilent Technologies). Chromatography was performed using an Allure PFP Propyl column (5 μm, 50 x 2.1 mm; Restek, Bellefonte, PA, USA): eluent A – methanol containing 0.1% formic acid, eluent B – water containing 0.1% formic acid); 20 % A (0 - 2 min.) followed by a linear gradient up to 80 % A at 22 min, 80 % A for 1 min, linear gradient down to 20 % A at 25 min, 20 % A for 5 min (run-time 30 min); flow rate of 600 μL/min, 10 μL of a 50 μg/mL injected. The mass spectrometer was run in ESI mode (m/z 70–500, with a fragmentor voltage set at 90 V for in-source CID).




# Supporting Information – Drug Testing and Analysis




Supporting Information – Drug Testing and Analysis

| Calc. m/z | Formula            | 2-APBT   |                | 3-APBT    |                | 4-APBT   |                | 5-APBT   |                | 6-APBT       |                | 7-APBT   |                |
|-----------|--------------------|----------|----------------|-----------|----------------|----------|----------------|----------|----------------|--------------|----------------|----------|----------------|
|           |                    | Obs. m/z | $\Delta$ (ppm) | Obs. m/z  | $\Delta$ (ppm) | Obs. m/z | $\Delta$ (ppm) | Obs. m/z | $\Delta$ (ppm) | Obs. m/z     | $\Delta$ (ppm) | Obs. m/z | $\Delta$ (ppm) |
| 192.0842  | $C_{11}H_{14}NS^+$ | 192.0842 | 0              | 192.0842  | 0              | 192.0842 | 0              | 192.0842 | 0              | No $[M+H]^+$ |                | 192.0842 | 0              |
| 175.0576  | $C_{11}H_{11}S^+$  | 175.0576 | 0              | 175.0576  | 0              | 175.0576 | 0              | 175.0576 | 0              | 175.0576     | 0              | 175.0576 | 0              |
| 160.03412 | $C_{10}H_8S^+$     | –        | –              | 160.03412 | 0              | –        | –              | –        | –              | –            | –              | –        | –              |
| 149.0420  | $C_9H_9S^+$        | 149.0420 | 0              | –         | –              | –        | –              | –        | –              | –            | –              | –        | –              |
| 147.0263  | $C_9H_7S^+$        | –        | –              | 147.0263  | 0              | 147.0263 | 0              | 147.0263 | 0              | 147.0263     | 0              | 147.0263 | 0              |
| 142.0777  | $C_{11}H_{10}^{+}$ | –        | –              | –         | –              | 142.0777 | 0              | 142.0777 | 0              | –            | –              | –        | –              |
| 135.0263  | $C_8H_7S^+$        | –        | –              | –         | –              | –        | –              | 135.0263 | 0              | –            | –              | –        | –              |
| 134.0185  | $C_8H_6S^{+}$      | 134.0185 | 0              | 134.0185  | 0              | –        | –              | –        | –              | –            | –              | –        | –              |
| 58.0651   | $C_3H_8N^+$        | –        | –              | –         | –              | –        | –              | –        | –              | –            | –              | 58.0651  | 0              |
| 44.0495   | $C_2H_6N^+$        | 44.0495  | 0              | 44.0495   | 0              | –        | –              | –        | –              | –            | –              | –        | –              |


4- and 5-APBT



5-APBT









7-APBT



Proposed fragments related to 2-APBT and 3-APBT shown in main text of manuscript

Supporting Information – Drug Testing and Analysis


HPLC-DAD UV spectra







Supporting Information – Drug Testing and Analysis

2-APBT HCl  
<sup>1</sup>H-NMR (600 MHz)  
d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis

2-APBT HCl  
COSY (600 MHz)  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

2-APBT HCl  
HSQC  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis

2-APBT HCl  
HMBC  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis

3-APBT HCl  
<sup>1</sup>H-NMR (600 MHz)  
d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis

3-APBT HCl  
COSY (600 MHz)  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis







Supporting Information – Drug Testing and Analysis

3-APBT HCl  
HSQC  
d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis

3-APBT HCl  
HMBC  
d<sub>6</sub>-DMSO



Supporting Information – Drug Testing and Analysis


4-APBT HCl  
<sup>1</sup>H-NMR (600 MHz)  
 d<sub>6</sub>-DMSO



8.31  
 7.92  
 7.84  
 7.83  
 7.77  
 7.76  
 7.76  
 7.34  
 7.32  
 7.25  
 7.24



3.50  
 3.50  
 3.48  
 3.47  
 3.46  
 3.45  
 3.44  
 3.43  
 3.43  
 3.42  
 3.42  
 3.40  
 3.33  
 3.03  
 3.01  
 3.01  
 2.99

1.15  
 1.13




Supporting Information – Drug Testing and Analysis

4-APBT HCl  
COSY (600 MHz)  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

4-APBT HCl  
HSQC  
d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis

4-APBT HCl  
HMBC  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis






Supporting Information – Drug Testing and Analysis

5-APBT HCl  
COSY (600 MHz)  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

5-APBT HCl  
HSQC  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis

5-APBT HCl  
HMBC  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis

6-APBT HCl  
<sup>1</sup>H-NMR (600 MHz)  
 d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis

6-APBT HCl  
COSY (600 MHz)  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis



Supporting Information – Drug Testing and Analysis



6-APBT HCl  
HSQC  
d<sub>6</sub>-DMSO







Supporting Information – Drug Testing and Analysis

6-APBT HCl  
HMBC  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis

7-APBT HCl  
<sup>1</sup>H-NMR (600 MHz)  
d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis

7-APBT HCl  
COSY (600 MHz)  
d<sub>6</sub>-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

7-APBT HCl  
HSQC  
d<sub>6</sub>-DMSO




Supporting Information – Drug Testing and Analysis



7-APBT HCl  
HMBC  
d<sub>6</sub>-DMSO



2-APBT HCl – ATR-IR





2-APBT base – ATR-IR








2-APBT base – GC-sIR





3-APBT HCl – ATR-IR





3-APBT base – ATR-IR




3-APBT base – GC-sIR





4-APBT HCl – ATR-IR




4-APBT base – ATR-IR



4-APBT base – GC-sIR




5-APBT HCl – ATR-IR







5-APBT base – ATR-IR




5-APBT base – GC-sIR





6-APBT HCl – ATR-IR




6-APBT base – ATR-IR




6-APBT base – GC-sIR





7-APBT HCl – ATR-IR



7-APBT base – ATR-IR



7-APBT base – GC-sIR





## Supporting Information – Drug Testing and Analysis




| Isomer |               | Aromatic ring C-C stretches<br>(1400–1500, 1585–1600 cm <sup>-1</sup> ) | Aromatic ring C-H in-plane bends<br>(1000–1250 cm <sup>-1</sup> )*                        | Aromatic C-H out-of-plane bends<br>(675–900 cm <sup>-1</sup> )** |
|--------|---------------|---|---|--|
| 2      | HCl (ATR-IR)  | 1430.5, 1456.4, 1496.9,<br>1575.2, 1602.0                               | 1005.3, 1015.0, 1066.1, 1088.5, 1111.7, 1124.0,<br>1154.3, 1197.4, 1251.1, 1228.5, 1253.9 | 709.2, 726.8, 756.1, 811.3, 844.2                                |
|        | Base (ATR-IR) | 1435.1, 1456.6, 1569.5  | 1014.8, 1066.3, 1120.0, 1132.8, 1155.5, 1187.3  | 707.9, 725.9, 743.5, 813.2, 858.5                                |
|        | Base (GC-sIR) | 1437.3, 1458.3, 1538.7,<br>1581.6                                       | 1015.9, 1066.6, 1120.7, 1133.4, 1155.4, 1183.6,<br>1215.1, 1255.3                         | 708.1, 728.1, 749.1, 812.7, 861.7                                |
| 3      | HCl (ATR-IR)  | 1425.5, 1459.0, 1515.1,<br>1539.1, 1568.5, 1592.7                       | 1021.4, 1043.6, 1092.8, 1130.5, 1156.3, 1210.1,<br>1243.3, 1262.8                         | 703.4, 736.9, 759.1, 767.6, 781.7, 834.1, 842.6                  |
|        | Base (ATR-IR) | 1426.1, 1457.6, 1576.9  | 1020.1, 1038.8, 1095.1, 1137.6, 1157.0, 1221.0,<br>1261.3                                 | 705.5, 730.3, 756.3, 766.9, 829.7                                |
|        | Base (GC-sIR) | 1427.4, 1459.0, 1580.3  | 1020.7, 1038.4, 1075.1, 1095.6, 1110.8, 1135.5,<br>1157.3, 1197.4, 1261.6                 | 705.1, 733.9, 758.8, 769.0, 827.3, 874.4                         |
| 4      | HCl (ATR-IR)  | 1411.8, 1450.9, 1461.9,<br>1515.9, 1569.4, 1589.7                       | 1055.1, 1091.0, 1117.7, 1129.2, 1155.4, 1167.4,<br>1209.1, 1239.5, 1257.9                 | 690.8, 710.3, 758.9, 798.5, 860.3                                |
|        | Base (ATR-IR) | 1412.2, 1450.9, 1570.5  | 1053.9, 1088.0, 1164.3, 1203.3  | 689.3, 702.4, 758.4, 796.1, 818.1, 860.3                         |
|        | Base (GC-sIR) | 1413.2, 1452.3, 1582.9  | 1048.8, 1085.2, 1132.4, 1150.2, 1163.8, 1205.1,<br>1252.2                                 | 689.4, 703.7, 762.2, 796.3, 829.5, 861.4                         |
| 5      | HCl (ATR-IR)  | 1421.0, 1437.7, 1499.6, 1605.0  | 1000.8, 1021.6, 1050.4, 1085.4, 1128.8, 1145.5,<br>1211.0, 1224.8, 1251.0                 | 694.6, 714.3, 770.0, 798.9, 836.5                                |
|        | Base (ATR-IR) | 1421.6, 1435.7, 1455.7, 1570.9  | 1050.1, 1089.0, 1145.7, 1159.7, 1224.2, 1261.4  | 689.5, 703.4, 754.7, 769.1, 800.8, 831.9, 894.0                  |
|        | Base (GC-sIR) | 1421.5, 1437.0, 1504.9,<br>1581.4, 1605.4                               | 1051.0, 1072.5, 1089.0, 1109.9, 1134.4, 1146.0,<br>1159.5, 1224.9, 1261.7                 | 690.5, 705.5, 756.9, 768.9, 801.8, 832.7, 868.3,<br>895.2        |
| 6      | HCl (ATR-IR)  | 1466.2, 1497.1, 1570.9, 1617.6  | 1015.7, 1050.2, 1085.5, 1126.4, 1144.4, 1202.6,<br>1245.1                                 | 702.4, 716.5, 763.2, 787.2, 806.2, 840.2, 889.4                  |
|        | Base (ATR-IR) | 1439.0, 1462.5, 1478.8, 1571.7  | 1047.5, 1083.3, 1093.2, 1185.5, 1203.6, 1261.9  | 691.5, 755.9, 785.9, 807.2, 836.5, 885.3                         |
|        | Base (GC-sIR) | 1451.8, 1465.5, 1490.2,<br>1581.0, 1604.9                               | 1019.1, 1048.2, 1072.6, 1084.2, 1104.4, 1133.3,<br>1170.9, 1203.1, 1261.5                 | 694.9, 710.4, 757.6, 785.7, 806.9, 837.7, 882.1                  |
| 7      | HCl (ATR-IR)  | 1459.3, 1506.4, 1572.9  | 1041.5, 1094.2, 1134.8, 1167.8, 1208.5, 1261.0  | 700.4, 773.7, 786.3, 835.5, 885.0                                |
|        | Base (ATR-IR) | 1458.0, 1572.9  | 1038.0, 1084.5, 1106.4, 1164.5, 1220.1  | 686.4, 701.8, 773.5, 791.2, 833.6                                |
|        | Base (GC-sIR) | 1395.4, 1459.0, 1574.1  | 1038.7, 1082.6, 1106.6, 1113.3, 1164.7, 1220.5,<br>1254.3                                 | 704.7, 773.5, 792.6, 833.6, 867.6                                |

\* Also C–N stretch (aliphatic amines) from 1250–1020 cm<sup>-1</sup>




\*\* Also C–S stretches in this region

GC-sIR partial spectrum - overtone bands




Four adjacent hydrogens  
on benzene ring



Three adjacent hydrogens  
on benzene ring






Two adjacent hydrogens  
and one isolated hydrogen  
on benzene ring




Supporting Information – Drug Testing and Analysis

GC-sIR partial spectrum



Supporting Information – Drug Testing and Analysis

GC-sIR partial spectrum



Supporting Information – Drug Testing and Analysis

GC-sIR partial spectrum

